No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ENOV240621C55000
- 1.25
- 0.000.00%
15min DelayTrading May 15 11:56 ET
0.00High0.00Low
0.00Open1.25Pre Close0 Volume16 Open Interest55.00Strike Price0.00Turnover242.81%IV25.40%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type0.2279Delta0.0286Gamma35.88Leverage Ratio-0.4726Theta0.0008Rho8.18Eff Leverage0.0131Vega
Intraday
- 5D
- Daily
News
Enovis Initiated at Neutral by JP Morgan
Enovis Initiated at Neutral by JP Morgan
J.P. Morgan Initiates Enovis Corp(ENOV.US) With Hold Rating, Announces Target Price $53
J.P. Morgan analyst Robbie Marcus initiates coverage on $Enovis Corp(ENOV.US)$ with a hold rating, and sets the target price at $53.According to TipRanks data, the analyst has a success rate of 53.9%
Express News | Enovis Corp : JP Morgan Initiates Coverage With Neutral Rating; Price Target $53
We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
Alan Fournier's Strategic Moves in Q1 2024 Highlighted by Major Stake in Enovis Corp
Comments
The company's use of debt is seen as risky due to its EBIT loss and the liabilities it has. The balance sheet is not considered strong, but it could improve over time. The stock is considered quite risky.
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt 1
Needham analysts predict Enovis's new products, orthopedic market strength, and the Lima acquisition will exceed 2024 consensus. They also foresee Paragon 28 returning to roughly 20% revenue growth in 2024 due to new bunion-focused products, supply chain enhancements, and sales force growth.
Enovis CEO Matt Trerotola praised Shirley, Vogt, and Ross for their roles in the company's growth. He highlighted Shirley's influence on Enovis's transformation to a medtech firm, Vogt's contribution to the U.S. surgical business growth, and Ross's work in ensuring sustained growth in the P&R segment.
Enovis' falling revenue and absent profits might have led to a drop in share price. Viewing the total shareholder return and recent share price rise, the company may suggest investment potential if it shows sustainable long term growth.
Enovis's rise in liabilities and recent EBIT loss spark concerns about its debt use and future profitability. With a negative free cash flow of US$106m over the past year, the company's financial risk is evident. Balance sheet situation calls for caution due to dubious circumstances.
Read more